# Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19

> **NCT04884295** · PHASE1,PHASE2 · TERMINATED · sponsor: **ExeVir Bio BV** · enrollment: 27 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** XVR011

## Key facts

- **NCT ID:** NCT04884295
- **Lead sponsor:** ExeVir Bio BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-26
- **Primary completion:** 2022-03-18
- **Final completion:** 2022-03-18
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** The sponsor does not intend to start Part 2 (Phase 2) due to change in company strategy for phase 2 design. This early end of trial is not due to reasons of safety or lack of efficacy. Part 1 (Phase 1) is completed as per protocol.
- **Last updated:** 2022-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04884295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04884295, "Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04884295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*